Ensign Peak Advisors, Inc Cara Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $116,454 - $203,281	41,150 Added 86.41%	88,770 $251,000
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $27,384 - $68,712	5,600 Added 13.33%	47,620 $233,000
Q4 2022 Feb 13, 2023	BUY	$8.88 - $12.77 $159,396 - $229,221	17,950 Added 74.57%	42,020 $451,000
Q3 2022 Nov 14, 2022	SELL	$8.24 - $12.56 $27,439 - $41,824	-3,330 Reduced 12.15%	24,070 $225,000
Q3 2021 Nov 12, 2021	BUY	$11.55 - $16.06 $116,655 - $162,206	10,100 Added 58.38%	27,400 $423,000
Q2 2021 Aug 13, 2021	BUY	$12.38 - $29.19 $214,174 - $504,987	17,300 New	17,300 $247,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.